238Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice

Dose-Dependent Efficacy and Safety Toxicology of Hydroxypyridinonate Actinide Decorporation Agents in Rodents: Towards a Safe and Effective Human Dosing Regimen

(2013) Deborah I. Bunin et al.   RADIATION RESEARCH

Significance of Single Variables in Defining Adequate Animal Models to Assess the Efficacy of New Radionuclide Decorporation Agents: Using the Contamination Dose as an Example

(2012) Erin E. Jarvis et al.   DRUG DEVELOPMENT RESEARCH

Actinide chelation: biodistribution andin vivocomplex stability of the targeted metal ions

(2012) Birgitta Kullgren et al.   TOXICOLOGY MECHANISMS AND METHODS

Multidentate Terephthalamidate and Hydroxypyridonate Ligands: Towards New Orally Active Chelators

(2011) Rebecca J. Abergel et al.   HEMOGLOBIN

NIAID/NIH RADIATION/NUCLEAR MEDICAL COUNTERMEASURES PRODUCT RESEARCH AND DEVELOPMENT PROGRAM

(2010) Nathaniel Hafer et al.   HEALTH PHYSICS

STRUCTURE OF A SINGLE MODEL TO DESCRIBE PLUTONIUM AND AMERICIUM DECORPORATION BY DTPA TREATMENTS

(2010) P. Fritsch et al.   HEALTH PHYSICS

BIOMIMETIC ACTINIDE CHELATORS: AN UPDATE ON THE PRECLINICAL DEVELOPMENT OF THE ORALLY ACTIVE HYDROXYPYRIDONATE DECORPORATION AGENTS 3,4,3-LI(1,2-HOPO) AND 5-LIO(ME-3,2-HOPO)

(2010) Rebecca J. Abergel et al.   HEALTH PHYSICS

LAURISTON S. TAYLOR LECTURE: THE QUEST FOR THERAPEUTIC ACTINIDE CHELATORS

(2008) Patricia W. Durbin   HEALTH PHYSICS

Medical Countermeasures against Nuclear Threats: Radionuclide Decorporation Agents

(2008) David R. Cassatt et al.   RADIATION RESEARCH